Previous 10 | Next 10 |
Alnylam Pharmaceuticals (NASDAQ:ALNY) announces the initiation of a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), which is being developed as a treatment for hypertension. The trial will evaluate the efficacy and safety of zilebesira...
– KARDIA-2 will Evaluate Efficacy and Safety of Zilebesiran when Used in Combination with Conventional Antihypertensive Medications – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-2...
- Lumasiran Resulted in Substantial Reductions in Plasma Oxalate in PH1 Patients with Severe Renal Impairment - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ...
– Annual survey has ranked Alnylam within the top five on the best employers list since 2019 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ranked third in Science’s 2021 Top Emp...
Cantor Fitzgerald reiterated the overweight rating on Alnylam Pharmaceuticals (ALNY -1.6%) even after the company shares tanked on Thursday amid concerns over the departure of its founding CEO John Maraganore after 19-years at the helm. As the announcement coincided with worse than expec...
Image source: The Motley Fool. Alnylam Pharmaceuticals, inc (NASDAQ: ALNY) Q3 2021 Earnings Call Oct 29, 2021 , 8:30 p.m. ET Operator Continue reading For further details see: Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Tran...
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are tanking this week, falling 18.4% as of the market close on Thursday, according to data from S&P Global Market Intelligence . The decline came primarily after the company announced its third-quarter results on Thursday...
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2021 Earnings Conference Call October 28, 2021 08:30 ET Company Participants Christine Lindenboom - Investor Relations John Maraganore - Chief Executive Officer Yvonne Greenstreet - President & Chief Operating Officer Tolga Tanguler - Chief Commerci...
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
Gainers: HCW Biologics (NASDAQ:HCWB) +132%. InflaRx (NASDAQ:IFRX) +45%. Digital Brands Group (NASDAQ:DBGI) +43%. Lucid Group (NASDAQ:LCID) +38%. Wolfspeed (NASDAQ:WOLF) +32%. LendingClub Corporation (NYSE:LC) +32%. Overstock (NASDAQ:OSTK) +25%. Impinj (NASDAQ:PI) +24%. Triterras (NASDAQ:TRIT)...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...